Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

CD33 FPBMC

Phase 1Small molecule

UUniversity of Virginia

CD33 FPBMC is one of 19 small molecule programs targeting Phase IB. It is currently in Phase 1.

1

Indications

1

Total Trials

1

Active Trials

18

Competitors

Pipeline

Status by Indication[3][1]

Indication

Phase IBRecruiting

Phase IBPhase 1

Recruiting

Competition

Competitive Landscape

19 competitors in Phase IB

#DrugCompanyPhaseTrials

Cytosar

Ibrance

Kisqali

Verzenio

Afinitor

Bavencio

Lisaftoclax

Ascentage Pharma Group Inc.

Vidaza

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

R-CHOP

IIncyte Biosciences Japan GK

POLA-R-CHP

FFudan University

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2031

Phase 1Recruiting

Phase IB

NCT07270978

Clinical

Trials by Indication[1]

Phase IB1 trial

Phase Ib Study of CD33 FPBMC in Patients With MRD+ AML or MDS

Recruiting·UUniversity of Virginia·Phase 1·NCT07270978·23 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for CD33 FPBMC. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CD33 FPBMC compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CD33 FPBMC. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Virginia company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: UUniversity of Virginia

Related News